2.3
2022

Anti-IL5/5R in the treatment of chronic eosinophilic pneumonia and severe asthma

Show more: Authors information and Publication history
Authors Information

1Department of Allergy, La Paz University Hospital, Madrid, Spain
2Department of Pulmonology, La Paz University Hospital, Madrid, Spain
3La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
4CIBER of Respiratory Diseases (CIBERES), Madrid, Spain

History

Published: 11 January 2024
Accepted: 11 January 2024
Received: 13 October 2023

KEY WORDS
Chronic eosinophilic pneumonia; severe asthma; mepolizumab; reslizumab; benralizumab. 

Table of Content: Online First

European Annals of Allergy and Clinical Immunology ISSN 1764-1489 | © 2024